CA
NZ
UK
AU
IND
US
…
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-read sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, the company provides Revio, Vega, Sequel, Sequel II, and Sequel IIe instruments which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits. It serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies. The company markets its products through a sales force and distribution partners in Australia, certain parts of Asia, Europe, the Middle East, Africa, Central America, and South America. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -314.25M | -274.87M | 29.40M | -84.13M | -102.56M |
| Net income | -296.93M | -181.22M | 29.40M | -77.82M | -102.56M |
| Selling general administrative | 160.85M | 124.12M | 72.80M | 75.49M | 63.49M |
| Gross profit | 49.03M | 58.86M | 32.57M | 34.58M | 25.10M |
| Reconciled depreciation | 17.32M | 11.59M | 9.30M | 9.95M | 7.21M |
| Ebit | -304.82M | -178.16M | -104.39M | -100.55M | -107.35M |
| Ebitda | -297.18M | -178.07M | -102.33M | -99.52M | -100.14M |
| Depreciation and amortization | 7.64M | 0.09M | 2.06M | 1.02M | 7.21M |
| Non operating income net other | - | 0.09M | 2.06M | 1.02M | 0.85M |
| Operating income | -304.82M | -178.16M | -104.39M | -100.55M | -100.99M |
| Other operating expenses | 433.12M | 308.68M | 183.28M | 191.44M | 179.61M |
| Interest expense | 14.69M | 12.53M | 0.27M | 2.61M | 2.42M |
| Tax provision | 0.00M | -93.65M | - | - | - |
| Interest income | - | - | - | 2.61M | 2.42M |
| Net interest income | -14.69M | -12.53M | -0.27M | -2.61M | -2.42M |
| Non recurring | - | 31.13M | - | - | - |
| Income tax expense | -17.32M | -93.65M | -6.98M | -6.32M | 0.85M |
| Total revenue | 128.30M | 130.51M | 78.89M | 90.89M | 78.63M |
| Total operating expenses | 353.85M | 237.02M | 136.95M | 135.12M | 126.08M |
| Cost of revenue | 79.27M | 71.65M | 46.33M | 56.31M | 53.53M |
| Total other income expense net | -9.43M | -96.71M | 133.79M | 16.41M | 0.85M |
| Net income from continuing ops | -314.25M | -181.22M | -102.60M | -102.13M | -102.56M |
| Net income applicable to common shares | -314.25M | -181.22M | 29.40M | -84.13M | -102.56M |
| Breakdown | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Total assets | 1260.45M | 1746.01M | 1767.09M | 2006.97M | 413.98M |
| Intangible assets | 389.57M | 456.98M | 410.25M | 410.98M | - |
| Other current assets | 19.47M | 17.04M | 10.29M | 12.49M | 4.87M |
| Total liab | 753.85M | 1044.71M | 1204.18M | 1215.98M | 78.49M |
| Total stockholder equity | 506.59M | 701.30M | 562.90M | 790.99M | 335.49M |
| Other current liab | 35.84M | 53.54M | 21.87M | 28.55M | 18.29M |
| Common stock | - | 0.27M | 0.23M | 0.22M | 0.19M |
| Capital stock | 0.29M | 0.27M | 0.23M | 0.22M | 0.19M |
| Retained earnings | -2148.93M | -1839.08M | -1532.34M | -1218.09M | -1036.87M |
| Other liab | - | - | 2.60M | 214.97M | 10.29M |
| Good will | 317.76M | 462.26M | 409.97M | 409.97M | - |
| Other assets | - | 0.00M | 13.45M | 1.17M | 33.49M |
| Cash | 55.37M | 180.21M | 325.09M | 460.73M | 318.81M |
| Total current liabilities | 66.30M | 95.03M | 76.92M | 83.29M | 36.49M |
| Current deferred revenue | 13.86M | 16.34M | 32.29M | 36.03M | 10.29M |
| Net debt | 617.06M | 753.72M | 632.28M | 493.02M | -276.81M |
| Short term debt | 20.05M | 10.08M | 10.73M | 7.71M | 4.33M |
| Short long term debt | - | 0.49M | 1.84M | - | - |
| Short long term debt total | 672.43M | 933.93M | 957.37M | 953.75M | 42.00M |
| Other stockholder equity | 2655.10M | 2539.89M | 2099.78M | 2009.94M | 1372.08M |
| Property plant equipment | - | - | 81.34M | 79.12M | 24.90M |
| Total current assets | 495.68M | 742.05M | 855.00M | 1105.73M | 354.75M |
| Net tangible assets | - | - | -257.31M | -29.97M | 335.49M |
| Short term investments | 334.56M | 451.50M | 447.23M | 583.67M | 237.20M |
| Net receivables | 27.52M | 36.62M | 18.79M | 24.24M | 16.84M |
| Long term debt | 647.49M | 892.24M | 896.68M | 896.07M | - |
| Inventory | 58.76M | 56.68M | 50.38M | 24.60M | 14.23M |
| Accounts payable | 16.59M | 15.06M | 12.03M | 11.00M | 3.58M |
| Accumulated other comprehensive income | 0.42M | 0.22M | -4.76M | -1.09M | 0.09M |
| Common stock total equity | - | - | - | 0.22M | 0.19M |
| Retained earnings total equity | - | - | - | -1218.09M | -1036.87M |
| Non currrent assets other | 10.84M | -443.71M | 10.53M | 1.17M | 4.38M |
| Non current assets total | 764.77M | 1003.97M | 912.09M | 901.24M | 59.23M |
| Capital lease obligations | 24.94M | 41.20M | 49.96M | 57.68M | 42.00M |
| Long term debt total | - | - | - | 896.07M | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | 116.08M | -352.81M | -218.28M | 64.88M | -36.56M |
| Change to liabilities | -2.71M | 32.10M | 4.08M | 1.57M | -2.51M |
| Total cashflows from investing activities | 116.08M | -678.53M | -219.32M | 62.05M | -38.41M |
| Net borrowings | -1.61M | 895.17M | -16.00M | -16.00M | -16.00M |
| Total cash from financing activities | 9.62M | 1169.58M | 251.84M | 26.55M | 107.18M |
| Change to operating activities | -22.81M | 8.50M | 4.28M | -4.09M | -0.59M |
| Net income | -314.25M | -181.22M | 29.40M | -84.13M | -102.56M |
| Change in cash | -137.51M | 379.87M | 52.02M | 10.28M | 2.34M |
| Begin period cash flow | 465.82M | 85.95M | 33.93M | 23.34M | 21.01M |
| End period cash flow | 328.31M | 465.82M | 85.95M | 33.63M | 23.34M |
| Total cash from operating activities | -263.21M | -111.18M | 19.50M | -78.31M | -66.43M |
| Issuance of capital stock | 0.00M | 294.85M | 187.48M | 0.00M | 97.53M |
| Depreciation | 17.32M | 11.59M | 9.30M | 9.95M | 7.21M |
| Other cashflows from investing activities | - | -319.79M | - | 64.88M | -36.56M |
| Change to inventory | -33.91M | -12.43M | -1.10M | 3.92M | 3.62M |
| Change to account receivables | 5.46M | -7.17M | -1.60M | -6.67M | 4.84M |
| Sale purchase of stock | - | 326.65M | 233.84M | 8.55M | 107.18M |
| Other cashflows from financing activities | 116.08M | 875.10M | 80.36M | 18.00M | 9.65M |
| Change to netincome | 87.05M | 36.91M | -16.47M | -1.42M | 22.99M |
| Capital expenditures | 16.93M | 5.93M | 1.04M | 2.84M | 1.85M |
| Change receivables | - | -7.17M | -1.60M | -6.67M | 4.84M |
| Cash flows other operating | - | 24.11M | -1.26M | 0.87M | -0.29M |
| Cash and cash equivalents changes | - | 379.87M | 52.02M | 10.28M | 2.34M |
| Change in working capital | -53.97M | 21.00M | -2.76M | -3.00M | 5.67M |
| Stock based compensation | 78.61M | 73.36M | 17.53M | 16.40M | 23.15M |
| Other non cash items | 9.08M | 57.75M | -33.87M | -16.79M | 1.02M |
| Free cash flow | -280.14M | -117.11M | 18.46M | -81.15M | -68.28M |
Sector: Healthcare Industry: Medical Devices
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| PACB Pacific Biosciences of California |
-0.29 10.17% |
2.60 | - | - | 2.04 | 3.39 | 4.38 | -4.15 |
| ABT Abbott Laboratories |
1.63 1.56% |
106.20 | 25.97 | 17.24 | 3.57 | 3.20 | 3.81 | 16.75 |
| MDT Medtronic PLC |
-0.57 0.59% |
96.54 | 26.60 | 15.87 | 3.35 | 2.08 | 3.90 | 14.12 |
| SYK Stryker Corporation |
-19.89 6.38% |
291.86 | 29.23 | 16.86 | 4.18 | 4.51 | 4.63 | 17.16 |
| SEMHF Siemens Healthineers AG |
-0.11 0.22% |
47.69 | 39.57 | 21.32 | 3.01 | 3.29 | 2.95 | 16.92 |
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-read sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, the company provides Revio, Vega, Sequel, Sequel II, and Sequel IIe instruments which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits. It serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies. The company markets its products through a sales force and distribution partners in Australia, certain parts of Asia, Europe, the Middle East, Africa, Central America, and South America. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.
| Name | Title | Year Born |
|---|---|---|
| Mr. Christian O. Henry M.B.A. | Pres, CEO & Director | 1968 |
| Ms. Susan G. Kim | Chief Financial Officer | 1976 |
| Mr. Mark Van Oene | Chief Operating Officer | 1973 |
| Dr. Denis Zaccarin Ph.D. | Sr. VP of Product Devel. | 1966 |
| Dr. Stephen Turner | Co-Founder & CTO | 1968 |
| Ms. Michele Farmer CPA | VP & Chief Accounting Officer | 1980 |
| Dr. Jonas Korlach Ph.D. | Chief Scientific Officer | NA |
| Trevin Rard | Head of Investor Relations | NA |
| Dr. Brett Atkins J.D., Ph.D. | Gen. Counsel & Corp. Sec. | NA |
| Ms. Natalie Welch | Chief People Officer | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-1.82%
Communication Services
-0.22%
Consumer Cyclical
-0.13%
Consumer Defensive
+0.32%
Energy
+0.15%
Financial Services
-0.85%
Financials
+2.34%
Healthcare
-1.28%
Industrials
-0.96%
Real Estate
-0.38%
Technology
-2.73%
Utilities
-0.31%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...